Multiple good news from SciBase

Friday, SciBase released several announcements.

Firstly; Q3 numbers were released showing good growth across the board and with especially good traction in the US. Also good to see, that opex is well under control.

Secondly; it was announced that SciBase offers to repurchase its outstanding TO2's and pay with shares. The vast amount of TO2's with exceptional long time to exercise in our view creates an overhang that do not benefit the share price. At LSIF - together with an affiliated investor - we support this measure by committing to swap well in excess of 20 million TO2's, and we hope to see a generel conversion rate as close to 100% as possible.

Thirdly; SciBase announced a rights issue with the aim of raising SEK 83 million for further expansion. Although we do not regard a rights issue as optimal under the current market conditions, we find it encouraging with the support from all the largest shareholders, and LSIF also intends to support this measure.

Fourthly; it was announced, that the collaboration with Castle Biosciences will already be expanded only a few months after being initiated. We view this as a major positive announcement and having met with Castle ourselves, we regard this development as having the potential to lead to an even more interesting development.

All in all a very good Friday for SciBase and its shareholders, and the short term negative share reaction due to the rights issue, we regard as likely just to be a bump on the road.

At LSIF, we look forward to what we believe can be a very interesting 2026 for the shareholders in SciBase.